FI831169A7 - Tuotteita ja menetelmiä syövän hoitoon. - Google Patents

Tuotteita ja menetelmiä syövän hoitoon. Download PDF

Info

Publication number
FI831169A7
FI831169A7 FI831169A FI831169A FI831169A7 FI 831169 A7 FI831169 A7 FI 831169A7 FI 831169 A FI831169 A FI 831169A FI 831169 A FI831169 A FI 831169A FI 831169 A7 FI831169 A7 FI 831169A7
Authority
FI
Finland
Prior art keywords
products
methods
treating cancer
cancer
treating
Prior art date
Application number
FI831169A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI831169L (fi
FI831169A0 (fi
Inventor
David Stephen Terman
Joseph P Balint
John J Langone
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of FI831169A0 publication Critical patent/FI831169A0/fi
Publication of FI831169L publication Critical patent/FI831169L/fi
Publication of FI831169A7 publication Critical patent/FI831169A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FI831169A 1982-04-07 1983-04-06 Tuotteita ja menetelmiä syövän hoitoon. FI831169A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36643682A 1982-04-07 1982-04-07
US47236283A 1983-03-11 1983-03-11

Publications (3)

Publication Number Publication Date
FI831169A0 FI831169A0 (fi) 1983-04-06
FI831169L FI831169L (fi) 1983-10-08
FI831169A7 true FI831169A7 (fi) 1983-10-08

Family

ID=27003359

Family Applications (1)

Application Number Title Priority Date Filing Date
FI831169A FI831169A7 (fi) 1982-04-07 1983-04-06 Tuotteita ja menetelmiä syövän hoitoon.

Country Status (13)

Country Link
EP (1) EP0091784B1 (OSRAM)
AU (2) AU569467B2 (OSRAM)
CA (1) CA1230555A (OSRAM)
DE (1) DE3374756D1 (OSRAM)
DK (1) DK154283A (OSRAM)
ES (5) ES521279A0 (OSRAM)
FI (1) FI831169A7 (OSRAM)
GB (2) GB2119803B (OSRAM)
GR (1) GR78514B (OSRAM)
NO (5) NO831223L (OSRAM)
PT (1) PT76505B (OSRAM)
RO (3) RO86661A (OSRAM)
ZW (1) ZW7583A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2161813B (en) * 1984-07-20 1988-07-13 Michiko Koga Anti-tumor agent
GB9013872D0 (en) * 1990-06-21 1990-08-15 Inst Tecnologico Y Cientifico Use of protein a and polypeptide components thereof in the treatment of tumours
CA2160155A1 (en) * 1993-04-08 1994-10-27 Stella Nowicki Model for gonococcal infection
GB2422311A (en) * 2005-01-20 2006-07-26 Martin Lister Treatment of blood to cure disease
DE102005012594A1 (de) 2005-03-18 2006-09-21 Bayer Technology Services Gmbh Elektrofiltrationsverfahren
BRPI1010642A2 (pt) * 2009-05-14 2016-03-15 Oatmeal Biotechnologies Group L L C tecnologias de plataforma para doenças ocorrendo espontaneamente
WO2017189919A2 (en) 2016-04-28 2017-11-02 Alkahest, Inc. Blood plasma and plasma fractions as therapy for tumor growth and progression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132769A (en) * 1974-10-30 1979-01-02 Osther Kurt B Cancer antigen, cancer therapy, and cancer diagnosis
US4146603A (en) * 1977-02-18 1979-03-27 Research Corporation Tumor specific glycoproteins and method for detecting tumorigenic cancers
SE7904276L (sv) * 1978-05-17 1979-11-18 Benzon As Alfred Renat cancerassocierat protein

Also Published As

Publication number Publication date
GB2163164A (en) 1986-02-19
RO86661A (ro) 1986-07-30
NO831223L (no) 1983-10-10
RO89498A (ro) 1986-06-30
NO841496L (no) 1983-10-10
ES8503954A1 (es) 1985-04-16
CA1230555A (en) 1987-12-22
ES8405621A1 (es) 1984-06-16
GB8309348D0 (en) 1983-05-11
EP0091784B1 (en) 1987-12-02
ES528119A0 (es) 1985-04-16
NO841498L (no) 1983-10-10
RO89496A (ro) 1986-06-30
ES8503950A1 (es) 1985-04-16
ES528118A0 (es) 1985-04-16
ES8601703A1 (es) 1985-11-01
GB2119803B (en) 1986-09-03
AU569467B2 (en) 1988-02-04
EP0091784A2 (en) 1983-10-19
ES521279A0 (es) 1984-06-16
EP0091784A3 (en) 1984-07-11
FI831169L (fi) 1983-10-08
DE3374756D1 (en) 1988-01-14
GR78514B (OSRAM) 1984-09-27
DK154283A (da) 1983-10-08
AU1286583A (en) 1983-10-13
ES528120A0 (es) 1985-04-16
FI831169A0 (fi) 1983-04-06
ES8503953A1 (es) 1985-04-16
ZW7583A1 (en) 1983-06-29
RO86661B (ro) 1985-03-01
PT76505A (en) 1983-05-01
GB8510892D0 (en) 1985-06-05
AU1560088A (en) 1988-10-27
PT76505B (en) 1986-05-05
NO841495L (no) 1983-10-10
ES528121A0 (es) 1985-11-01
NO841497L (no) 1983-10-10
GB2163164B (en) 1986-09-03
DK154283D0 (da) 1983-04-07
GB2119803A (en) 1983-11-23

Similar Documents

Publication Publication Date Title
FI803381A7 (fi) Koostumus ja menetelmä syövän toteamiseksi ihmisistä.
FI841522A0 (fi) Processtyrsystem med felsoekning.
DE3482024D1 (de) Haarbehandlungsapparat.
FI850700A7 (fi) Valmiste ja menetelmä aknen hoitoa varten.
FI842560A7 (fi) Menetelmä ihmisen syöpäkuolitekijän puhdistamiseksi ja valmistamiseksi.
DE3173016D1 (en) Preparations for the treatment of dermatoses
FI833116A7 (fi) Farmaseuttisia valmisteita haitallisten yhteenkasvamien käsittelemiseksi sekä niiden käyttö.
DE3484958D1 (de) Flaechenbehandlungsverfahren.
FI834730A7 (fi) 1-karboksialkanoyyliperhydroindoli-2- karboksyylihapot ja niiden johda nnaiset.
FI832519A7 (fi) Farmaseuttisia menetelmiä ja koostumuksia.
FI812834A7 (fi) Menetelmä ja laite vinassin käsittelemiseksi.
FI831169A7 (fi) Tuotteita ja menetelmiä syövän hoitoon.
FI832569A7 (fi) Laite aineiden lämpökäsittelemiseksi.
IT8224181A0 (it) Procedimento e disposizione per trattare termicamente pezze in movimento.
FI832520A7 (fi) Farmaseuttisia menetelmiä ja koostumuksia.
FI830721A7 (fi) Menetelmä ja laite tukkien reunojen jyrsimiseksi.
FI854834A7 (fi) Laite ja menetelmä eläinten hoitamiseksi.
IT8322785A0 (it) Metodo e composizione per il trattamento di tumori.
NL188779C (nl) Microgolfoven.
EP0139005A4 (en) ANTITUMOR COMPOSITION, METHOD FOR TREATING TUMORS AND USE OF THE COMPOSITION FOR TREATING TUMORS.
FI833443A7 (fi) 1,2,3,4-tetrahydro-1-aminometyyli-4- fenyyli-isokinoliinit ja niiden valmistusmenetelmät.
FI820342A7 (fi) Tulehdusten hoitaminen.
IT8123860A0 (it) 4-carbamoilossi-ossazafosforine metodo per produrle e preparazioni farmaceutiche che le contengono.
FI823625A7 (fi) Menetelmä selluloosapitoisen aineen käsittelemiseksi.
FI800491A7 (fi) Menetelmä ja laite hiukkasmaisen aineen käsittelemiseksi.

Legal Events

Date Code Title Description
FA Application withdrawn [patent]

Owner name: BAYLOR COLLEGE OF MEDICINE